B7-33

B7-33 is a preclinical compound — all existing research is animal-based, with no completed human trials on record and no community use data captured in TVR's corpus. There is no FDA-approved indication, and any human use is off-label or compounded. This page will expand as human data and community reports emerge; for now, the accurate picture is that B7-33 has not crossed into documented human use at any meaningful scale, and no protocol guidance exists to draw from.

B7-33

Research Evidence

Evidence shape

B7-33 has no registered clinical trials anywhere in the record. The one mapped indication — preclinical and mechanistic research — reflects where this compound currently lives: animal models, not human subjects. There are no blinded studies, no posted results, and no trial registry entries pointing toward active clinical development. For readers assessing human applicability, that absence is the answer: B7-33 has not entered the testing pipeline that generates human evidence.

Depthhow much
0 registered trials
Breadthhow many areas
1 indication mapped
1 animal-only
Qualityhow rigorous
No completed trials
Breadth and depth4 rows captured
Human
direct clinical signal
0
Animal
translational support
2
In vitro
mechanistic support
2
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

1
Kensington Labs
UK
10 mg
$47.02
$4.7/mg
2
Direct Peptides Japan
JP
6 mg
$45.28
$7.54/mg
3
Core Peptides
US
6 mg
$60.00
$10/mg
4
Biotech Peptides
US
6 mg
$62.00
$10.33/mg

price offers can be sorted by column

Dosing & Protocol

How B7-33 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = Preclinical only
Typical dose
1 µg1 µg – 1 mg
1 µg
10 µg
100 µg
1 mg
Frequency
varied
Timing
varied
Route
subQ
Cycle
varied

Research on B7-33 is exclusively in preclinical/mechanistic animal models, exploring its anti-fibrotic potential in cardiac, renal, and pulmonary contexts. No human clinical trials are currently registered.

Clinician practice
Doctor & published-protocol guidance
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for B7-33, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.